Arax Advisory Partners’s Enveric Biosciences ENVB Stock Holding History

Arax Advisory Partners’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$12	Buy	+8	New	+$12	﹤0.01%	5348

Other funds holding ENVB

AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Arax Advisory Partners's ENVB Position: Q3 2026 in Review

Arax Advisory Partners opened a new position in Enveric Biosciences (ENVB) in Q3 2026: 8 shares worth $12. The stake represents ﹤0.01% of the portfolio and ranks #5348 among its holdings.

13 funds tracked by Wall St. Rank hold ENVB as of Q3 2026.

Arax Advisory Partners held 8 shares of Enveric Biosciences worth $12 as of Q3 2026.
Enveric Biosciences was a new Arax Advisory Partners position in Q3 2026.
Enveric Biosciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #5348 holding.
13 funds tracked by Wall St. Rank held Enveric Biosciences as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.